Overview
Prevention of transplant rejection during allogeneic transplantation of the kidney, heart, lungs and other organs, as well as in bone marrow transplantation and to reduce the transplant rejection reaction in patients previously treated with other immunosuppressants
Dysfunction of the kidneys, liver, gastrointestinal tract (nausea, vomiting, anorexia), gum hyperplasia, thrombocytopenia, fluid retention, convulsions, etc.
DOSAGE AND ADMINISTRATION
Intravenously and intravenously. Cyclosporin is administered in / in slowly (dropwise) in an isotonic sodium chloride solution or 5% glucose solution. The initial https://zentherapycenter.com/let-s/sandimmune.php is usually with the introduction of iv 3-5 mg / kg per day, when taken orally - 10-15 mg / kg per day. Next, doses are selected based on the concentration of cyclosporine at blood. Determination of concentration must be done daily. For research, the radioimmunological method using special there is used. The use of cyclosporine should be done only by Bendrox with sufficient experience in immunosuppressant therapy. When transplanting organs, cyclosporine is administered 4-12 hours before the transplantation operation, when a bone marrow transplant is performed on the eve of the operation. Typically, the initial dose is administered iv and iv is continued for 2 weeks. Then they switch to oral maintenance therapy. It should be remembered treated cyclosporine has high nephro- and hepatotoxicity. The main principle of the optimal use of the drug is a balanced choice between an individual immunosuppressive dose health a tolerated (non-toxic).
Cyclophosphamide (Cyclophosphanum) Cyclophosphamide *
Cytostatic, antitumor, immunosuppressive. It is activated in tumor cells under the influence of phosphatases contained in them in large numbers, attacks the nucleophilic centers of protein molecules, disrupts the synthesis of DNA and RNA, and blocks the mitotic division of tumor cells.
cure FOR USE
Small-cell lung cancer, ovarian cancer, breast cancer, reticulosarcoma, lymphosarcoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, multiple myeloma, Wilms tumor, Ewing's tumor, bone reticulosarcoma, angiosarcoma.
Severe anemia, leukopenia, thrombocytopenia, cachexia, terminal stages of the disease
RESTRICTIONS FOR USE
Severe heart, liver, and kidney disease.
Leukopenia up to agranulocytosis, thrombocytopenia, cardiotoxic effects, nausea, vomiting, partial or complete alopecia, dizziness, blurred vision, dysuria, hematuria, ossalgia, febrile syndrome, chills. An overdose is manifested by pancytopenia, dilated cardiomyopathy syndrome, indomitable vomiting, hemorrhagic cystitis.
Increases cardiotoxicity of adriamycin and rubromycin. Myelodep recession is enhanced by allopurinol. The effect is increased by chlorpromazine, tricyclic antidepressants, barbiturates, theophylline, hingamine, thyroid hormones, and they reduce (including toxic) glucocorticoids and hporam-phenicol.
In the process of treatment, constant monitoring of the peripheral blood picture is necessary. If leukopenia (below 2.5 thousand in 1 μl) and / or thrombocytopenia (below 1CO thousand in 1 μl) appears, treatment should be discontinued. When prescribing Bendrox doses for the prevention of hemorrhagic cystitis, the appointment of uromitexan is indicated.
DOSAGE AND ADMINISTRATION
Inside, in / in, in / m, in a cavity. Different treatment regimens are used: 3 mg / kg daily or 6 mg / kg every other day; 15 mg / kg once every 5 days or 30-45 mg / Bendrox once every 2-3 weeks iv. The course dose for all schemes is 6-14 g. After the main course of treatment, maintenance therapy can be used - 2 another a week 0.1-0.2 g iv or IM or 2 times a day - 0.05-01 g inside As an immunosuppressive agent, from 1 to 4 mg / kg are prescribed (if well tolerated).
CINNARIZIN * (Cinnarizin)
Reduces the tone of the smooth muscles of the arterioles, reduces the response to biogenic vasoconstrictor substances (adrenaline, norepinephrine, bradykinin). It has moderate antihistamine activity, reduces the excitability of the vestibular apparatus. Has a fairly high tropism to the vessels of the brain. Improves cerebral and coronary circulation. In patients with impaired peripheral circulation, improves blood circulation and potentiates postischemic hyperemia. It blocks “slow” calcium channels, reduces the intake of calcium ions into cells and reduces their content in the depot, inhibits the contractility of smooth muscle elements. When ingested, it is rapidly and completely absorbed. It is actively metabolized. 1/3 of the metabolites excreted in the urine, 2/3 - with feces.
INDICATIONS FOR USE
Cerebrovascular insufficiency (dizziness, tinnitus, decreased ability to concentrate, memory loss, senile psychoses), post-stroke conditions, convalescence after traumatic brain injury, migraine, Raynaud's disease, atherosclerosis obliterans, thrombangitis, diabetic angiopathy, acrocyanosis, disorders equilibrium (Meniere's syndrome, motion sickness), food allergy
RESTRICTIONS FOR USE
Drivers of vehicles, etc., performing work requiring concentration and a quick mental and physical reaction. Lactating women for the treatment period should refuse to breast-feed.
Fatigue, weakness, dizziness, Kineret, dry mouth, dyspeptic disorders, increased sweating, manifestations of lupus erythematosus, lichen planus, allergic reactions In elderly patients or when doses are prescribed more than 150 mg / day - tremor, muscle stiffness, hypokinesia 4 days after admission, a false result is possible when conducting skin allergy tests
The effect is enhanced by antidepressants, drugs that depress the central nervous system, alcohol. Incompatible with nootropics. Increases antihypertensive and vasodilator activity of other drugs.
